Peanut allergy

By Symon, Every Label · June 30, 2026

Peanut allergy is an IgE-mediated immune reaction to the seed-storage proteins in Arachis hypogaea, the peanut plant, and it is one of the most common causes of severe food anaphylaxis in children. In plain terms: your child’s immune system reads certain peanut proteins as a threat, and a reaction can run anywhere from hives to trouble breathing. It is a true allergy, not a sensitivity or an intolerance. About 2.2 percent of US children have peanut allergy (Gupta 2018), and for most of them it is lifelong, though roughly one in five outgrows it. It is also one of the most studied food allergies there is, which is why so much of what follows can be this specific, and, in places, this hopeful.

If your child was just diagnosed, read this first.

This page is long on purpose. It is also the page you will come back to for years, so it covers everything. You do not need all of it today. This week, this is what matters:

• Carry two epinephrine auto-injectors everywhere he goes, and learn the few signs that mean use one now. That is the section to read tonight (Emergency preparedness, below).
• Read every label, every time. The words to catch are peanut, arachis, and groundnut (Reading labels, below).
• You do not have to understand the protein science to keep him safe. The components, the test numbers, all of that is for unhurried conversations with your allergist, not for tonight.
• The allergy is usually narrower than it first looks. Most peanut-allergic kids safely eat other legumes like peas, soy, and chickpeas, even when a blood test flags them (Cross-reactivity, below).
• Peanut has more treatment options than almost any other food allergy, and they are real. There is time to get to that part (Treatment options, below).

Everything else here is waiting for you, in roughly the order the questions tend to come up. Read it when you want it, not because the page is making you.

Where a fact below is clinical, it carries its source. None of it is a substitute for your allergist.

What peanut allergy is, and who has it

Peanut allergy is an IgE-mediated immediate-type food allergy, and peanut is one of the leading causes of food-induced anaphylaxis, including the rare fatal kind, in children (Sicherer and Sampson 2018). That last fact is the reason for everything practical on this page: the auto-injectors, the label habit, the written plan. Those layers are what make the worst outcome rare. The mechanism underneath is quick. When your child eats peanut, IgE antibodies on his immune cells latch onto the peanut proteins and set off a release of histamine and other chemicals within minutes. That release is the reaction.

Peanut is a legume, not a tree nut. It grows underground, in the bean and pea family (Fabaceae), and it is botanically unrelated to almonds, cashews, and walnuts. That sounds like trivia, but it is actually good news: the foods peanut truly cross-reacts with are other legumes, and even most of those turn out to be safe (Cross-reactivity, below). The tree nuts peanut gets shelved next to are a separate question, not a shared protein.

In the United States, parent-reported peanut allergy runs about 2.2 percent of children (Gupta 2018, a nationally representative survey, parent-reported and not challenge-confirmed), which is roughly 1.6 to 1.8 million children. You are not dealing with something rare or strange. It is common enough that schools, airlines, and allergists all have established routines for it. Peanut allergy affects adults too, at a somewhat lower rate. Onset is usually early childhood, often before age two, frequently at the first known ingestion.

Diagnosis combines your child’s reaction history with testing. The next section is about what that testing can actually tell you, and it is more reassuring than it first looks.

The components that drive severity

Peanut is not one thing to the immune system. It is a handful of different proteins, and which ones your child reacts to changes how serious the allergy tends to be. This is the most useful, and often most reassuring, test you can ask about, so here is what it is actually for.

A standard peanut test (the skin prick, or the basic blood test) only tells you the immune system has noticed peanut at all. A more detailed test, called component testing, breaks that down protein by protein. It answers the question you actually care about: is this the kind of peanut allergy that can turn serious, or the milder, itchy-mouth kind? The answer is sometimes reassuring, and either way it shapes the plan.

For most parents, two results carry the weight:

• The one that can turn serious is the protein your allergist calls Ara h 2 (with its close partner, Ara h 6). A child who reacts to these has the kind of allergy that can go whole-body, so this is the result that matters most.
• The one that is usually mild is Ara h 8. If your child’s positivity is mostly to Ara h 8, that often points to the birch-pollen, itchy-mouth kind that tends not to progress to anaphylaxis. A scary-looking positive test that turns out to be mostly Ara h 8 is frequently the difference between a frightening result and a manageable one.

(One less common pattern, Ara h 9, matters more for families around the Mediterranean. It is in the deeper version below.)

So the high-value move is simple: ask your allergist to run component testing, and ask which components your child is sensitized to and what they mean for severity. You do not need to learn the protein names or the lab numbers yourself. They are right below, written so the words on your child’s lab report mean something when you want them to, not so you have to master them tonight.

Cross-reactivity, real and reassuring

Here is the part that surprises most parents, and it is good news: most peanut-allergic children safely eat most other legumes. Only a small minority of peanut-allergic people are clinically allergic to other legumes, and peas, soybeans, lentils, and chickpeas are usually fine to eat even when a blood test lights up for them. A positive test for another legume is usually co-sensitization, a flag without a fight, not a real-world allergy. So the alarming list a broad panel can produce is, in practice, usually much shorter.

There is a short list of cross-reactions that do matter, and they are worth knowing by name.

Lupin is the one to take seriously. Lupin and peanut cross-react, and a peanut-allergic person can develop a true lupin allergy through that overlap. Lupin flour turns up in European baked goods and gluten-free products and is not always obvious on a US label.

Fenugreek is the second. Peanut and fenugreek can cross-react, and fenugreek allergy often grows out of a primary peanut allergy. Fenugreek hides in curry powder, spice blends, and some maple-flavored products.

Pea protein isolate is the third, and it is showing up more and more in plant-based meats and protein powders, so it is worth a label check as those products spread.

What looks like cross-reactivity but usually is not. Soy and chickpea often show a positive test while real reactions stay much less common. A positive soy or chickpea result in a peanut-allergic child is usually not a reason to pull the food, but it is a reason to ask your allergist rather than guess.

Tree nuts are a “travels with,” not a “made of the same thing.” Many peanut-allergic children are also allergic to tree nuts, but through separate sensitization, not because they share proteins with peanut. Allergists test for both because the two co-occur, not because one causes the other. And coconut, despite the name and the FDA’s labeling rule, is botanically a fruit, and most tree-nut-allergic people tolerate it.

For the deep version, the protein-by-protein reason some related foods are safe and others are not, see peanut cross-reactivity.

Hidden sources

Peanut turns up in a few non-obvious places, and those are the ones parents miss, so they are worth a one-time read now.

Foods that are legumes, not “nuts.” Lupin flour, fenugreek, and pea protein isolate (all from the cross-reactivity section) are the legume-family hiding spots. Mandelonas, which are peanuts soaked in almond flavoring and sold as a nut substitute, are the one almost nobody has heard of, and they are simply peanuts under another name.

For the full label-scanning guide, the exact words to catch, the cuisines and non-food products peanut hides in, and the one labeling-law gap, see where peanut hides.

How exposure actually happens

This section is mostly reassuring, because the routes parents fear most are not the ones that cause serious reactions. Eating peanut is. The rest are lower-risk than they feel, with a couple of specific exceptions worth knowing.

Eating it (high). Swallowing peanut protein is the route that causes whole-body reactions. Everything else on this list is far behind it.

Skin contact (low, higher with eczema). Peanut on intact skin usually causes, at most, a local reaction where it touched. The real exception is broken or eczematous skin, where the risk is meaningfully higher (Lack 2003).

Breathing it in (low). Airborne peanut from someone eating nearby is low-risk for peanut specifically. The smell is roasting aroma, not protein floating in a dose that triggers a whole-body reaction. Steam from actively boiling or frying peanut is a separate, also-low category.

Kissing and saliva (documented, so worth a habit). Peanut protein is detectable in saliva and on hands for hours after eating it, and reactions passed by a kiss are documented. In practice this is about the after-school kiss and the playdate snack, a reason for a quick hand-and-mouth wash, not a reason to fear the air.

Airplanes. Cabin HEPA filters handle airborne particles. The practical risk is the tray table and the seat-back, which a wipe-down handles.

If your child is in treatment, one note: the risk levels above describe ordinary life outside active immunotherapy. During active OIT build-up, the risk from an incidental exposure is modulated, and the Treatment section is where that is explained.

Reading labels

This is the habit that does the most day-to-day work, and it gets fast. The words to scan for are peanut, peanuts, arachis, arachis oil, arachis hypogaea, and groundnut. Groundnut is the giveaway that slips past a US-trained eye; it is the common term in the UK, much of Africa, and India.

A few terms are ambiguous rather than clear-cut. Natural flavoring can occasionally hide peanut where ingredient rules are loose. Hydrolyzed vegetable protein does not always name its source plant. Mandelonas (from the hidden sources section) is the sleeper. When a term is unclear and the manufacturer will not say, treat it as a reason to call the company, not a reason to assume it is safe.

Then there are the precautionary labels: “may contain peanut,” “made in a facility that processes peanut,” “processed on shared equipment.” These are voluntary and unregulated in both the US and the EU, which means they are not a reliable signal of how much risk is actually present. How strictly you treat them is a personal call along a spectrum, weighing a real but variable cross-contact risk against ruling out a large share of the grocery store. This page will not pick that threshold for you, because the right answer depends on your child’s history and your own tolerance for the unknown.

Severity, and what predicts a bad reaction

The strongest predictor of a severe peanut reaction, across large groups of children, is sensitization to Ara h 2 and Ara h 6, the two proteins from the components section (Sicherer and Sampson 2018). A history of a previous severe reaction is the next strongest. After that, the threshold can move day to day: exercise, NSAID pain relievers, alcohol in older patients, a viral illness, and poor sleep can each lower it, and the Ara h 9 pattern is the most cofactor-sensitive.

Here is the part that justifies always carrying epinephrine. The size of the last reaction does not reliably predict the next one. A child whose worst reaction so far was hives can still have anaphylaxis on the next exposure. That is not a reason to live in fear. It is the single reason the auto-injector travels everywhere, regardless of how mild things have been. The unpredictability is exactly what the standing defenses are built for.

These thresholds are for the unmodified case. The above describes a peanut-allergic child who is not in active oral immunotherapy. During active OIT build-up dosing, the dose that can set off an incidental reaction is modulated, often downward, so this is the baseline and active treatment shifts it.

Emergency preparedness

Peanut anaphylaxis is treated epinephrine-first. Epinephrine is the first-line treatment for a severe reaction, not an antihistamine, and not a wait-and-see. If you see anaphylaxis, you give epinephrine and then you call emergency services.

The signs that mean epinephrine now include any two body systems reacting at once (for example hives plus vomiting), or any single severe sign on its own: trouble breathing, throat tightness, a hoarse or weak cry, repetitive coughing, pale or floppy appearance, or a sense of impending doom in a child old enough to say so. When you are unsure, the guidance is to give epinephrine, because the danger of withholding it in a true reaction is far greater than the danger of giving it when it turns out you did not need to.

After giving epinephrine, call emergency services and lay the child down with legs raised, unless breathing is the main problem, in which case let him sit up. A second dose may be needed if there is no improvement in about five minutes, or if symptoms progress. Every peanut-allergic child should have a written anaphylaxis action plan and two epinephrine auto-injectors that go everywhere the child goes.

This section is general. Your child’s own plan is the specific one, and it is the one to follow.

When you can’t tell what’s happening

The hardest moments are usually not the clear reactions. They are the ambiguous ones. A flushed cheek after a new food. A single cough. A child who says his tummy hurts an hour after a snack you did not pack. Telling the start of a reaction apart from an ordinary toddler complaint is genuinely hard, and it does not resolve cleanly from across the room.

The posture that works is to treat the spectrum, not to diagnose it in the moment. Know your action plan’s override signs cold, watch whether more than one body system is involved rather than fixating on a single symptom, and accept that you will sometimes give epinephrine or call the allergist for something that turns out to be nothing. That is the system working the way it is supposed to.

Treatment options

Strict avoidance is the floor, and everything else is decided on top of it. Avoidance plus a written action plan plus epinephrine within reach is the standing setup for most peanut-allergic children. It does not change the allergy; it is the safe ground the other options are built on. And there are real options now, more for peanut than for almost any other food allergy.

Peanut OIT (oral immunotherapy). OIT works by feeding measured, slowly increasing doses of peanut protein every day under medical supervision, training the body toward tolerance. Palforzia (AR101), a standardized defatted peanut-flour drug, was FDA-approved in 2020 for ages 4 through 17, the first and only FDA-approved peanut OIT product, given under a risk-management program. Its maker announced a voluntary global discontinuation of Palforzia, stated as unrelated to safety, quality, or efficacy. The exact discontinuation date is pending clinical review. Community (compounded) OIT, which uses store-bought peanut flour or defatted peanut under an allergist, is offered off-label by many practices. Starting doses, enrollment thresholds, and how fast the dose climbs vary by allergist and protocol, so this page does not name a starting dose. That is your allergist’s call, with you.

Omalizumab (Xolair). This is an anti-IgE antibody, given as an injection, FDA-approved in 2024 to reduce IgE-mediated reactions to one or more foods including peanut, for ages 1 and up. In the Phase 3 OUtMATCH trial, a majority of omalizumab-treated participants tolerated a meaningful amount of peanut protein without moderate-to-severe symptoms, compared with very few on placebo (Wood 2024). The specific percentages and dose are pending clinical review. It lowers the severity of an accidental exposure; it is not a cure, and it does not remove the need for avoidance and a plan.

SLIT and what’s coming. Sublingual immunotherapy (drops or a tablet held under the tongue) for peanut is still investigational, generally lower in efficacy but also lower in reactions than OIT. The wider pipeline includes the Viaskin peanut patch (a skin patch, still investigational) and other treatments in trials. This field moves fast; the above is where it stands as of writing.

Not medical advice. Which treatment, and whether to treat at all right now, is a conversation with your allergist.

Day-to-day living

School and day care. A peanut-allergic child needs a written plan on file, epinephrine truly accessible (not locked in a nurse’s office down a hall), trained staff, and a clear routine for snacks, classroom parties, and substitute teachers. In US public schools, a 504 plan is the usual way to put all of that in writing.

Restaurants. The risk is cross-contact and miscommunication, more than the menu. Asian, bakery, and ice cream spots carry higher peanut cross-contact risk. A chef card that states the allergy plainly does more than a verbal order relayed across a loud kitchen.

Travel. Bring more epinephrine than you think you need, carry food you trust, and wipe the airplane seat and tray. Pharmacies and emergency numbers differ by country, so look them up before you land, not during.

Holidays and gatherings. The dense-gathering stretches are the hard ones, because they multiply the settings you do not control. Bringing your child’s own food and being plain with hosts beats hoping a buffet is safe.

Prognosis and outgrowing

About one in five peanut-allergic children outgrow it, mostly in early childhood (Skolnick 2001; Ho 2008). The most useful early sign is a falling Ara h 2 level over time; a steadily low level is also favorable, while a high or rising one points to persistence. A shrinking skin-prick result over time points the same hopeful direction (Ho 2008).

Allergists usually reassess every one to three years, depending on history. The one definitive test of outgrowing it is a supervised oral food challenge; falling numbers are encouraging, but they are supportive, not proof.

Questions for your allergist

You do not have to walk in knowing the science. You have to walk in with the right questions, and these are them.

1. Which peanut components is my child sensitized to (Ara h 2, Ara h 6, Ara h 8, Ara h 9), and what does that pattern mean for us, serious-reaction risk versus the milder oral-allergy kind?
2. Given his component profile and history, what is his actual reaction risk, and which cofactors should I watch?
3. Which peanut-oil-containing medications and skin products should we avoid or flag to his other doctors?
4. Is he a candidate for OIT or omalizumab, and what are the trade-offs for us specifically?
5. If he is in or considering peanut OIT, how does active treatment change the day-to-day vigilance around incidental exposure, and how do exercise, illness, or missed doses change it?
6. When and how should we reassess to see if he is outgrowing it?

The frame: how to hold this

There are two worlds, and peanut allergy moves a family from one into the other. In the recoverable world, a mistake is a lesson. A forgotten jacket is a cold afternoon. In the irrecoverable world, one wrong protein is not a lesson, because the cost of the error can be the child. When someone tells a peanut parent to relax, they are speaking from the first world to someone who has had to move to the second. They think the parent is anxious. The parent is not anxious. The parent is calibrated.

The work, then, is to sort what is on your side of the line from what is not. On your side: the labels you read, the components you ask your allergist to run, the epinephrine that travels with the child, the chef card, the plan on file at school, the decision about OIT made with your allergist. Not on your side: the baker who changed a formula, the relative who thinks one bite is kindness, the manufacturer whose precautionary label is voluntary. You do the things on your side fully, and you stop apologizing for them. And you hold, without pretending otherwise, that the other side is real and partly random, and that a stacked defense reduces the risk without ever closing the gap to zero.

This page does not promise safety. It lays out the layers and names the gap, and it leaves the calibration to you and your allergist, who actually know your child.

Frequently asked questions

Is a peanut a tree nut?

No. Peanut is a legume, in the same family as peas and beans, and is botanically unrelated to tree nuts like almonds and cashews. Many peanut-allergic children are also allergic to tree nuts, but through separate sensitization, not because the two share proteins.

Can my peanut-allergic child eat other legumes like peas, soy, and chickpeas?

Usually yes. Most peanut-allergic children safely eat other legumes, and a positive blood test for one is often co-sensitization rather than a real allergy. Lupin is the main exception to take seriously. Confirm any change with your allergist rather than guessing.

Which peanut test result matters most?

Component testing for Ara h 2, with its partner Ara h 6. Sensitization to Ara h 2 marks the kind of allergy that can turn whole-body, while a result driven mainly by Ara h 8 often points to the milder, itchy-mouth kind.

Is there a treatment for peanut allergy?

There are real options now, more than for most food allergies: oral immunotherapy (OIT) and omalizumab (Xolair, FDA-approved in 2024 to reduce reactions). Neither is a cure, and both are decided with your allergist; strict avoidance plus epinephrine within reach stays the floor.

References

The claims on this page draw on the studies and guidance below. As new, credible research meaningfully changes the picture, we update the page to match.

• Gupta RS, et al. (2018). Prevalence and severity of food allergies among US children.
• Sicherer SH, Sampson HA (2018). Food allergy: epidemiology, pathogenesis, diagnosis, and treatment.
• Lack G, et al. (2003). Factors associated with the development of peanut allergy in childhood.
• Beyer K, et al. (2020). Component-resolved diagnostics in peanut allergy.
• Skolnick HS, et al. (2001); Ho MH, et al. (2008). Resolution (outgrowing) of peanut allergy.
• Wood RA, et al. (2024). Omalizumab for food allergy (OUtMATCH).
• AAAAI. Everything You Need to Know About Peanut Allergy (patient guidance; cross-reactivity and over-avoidance).
• Smits M, et al. (2023). Co-sensitization versus clinical reactivity in legume allergy. Frontiers in Allergy.
• Dooper MM, et al. (2009). Lupine and peanut cross-reactivity. Journal of Investigational Allergology and Clinical Immunology.